7月9日,默克公司(Merck & Co.)宣布将以每股美国存托股票107美元的价格,总计约100亿美元收购维罗纳制药(Verona Pharma)。由于旗下关键抗癌药物可瑞达(Keytruda,通用名:pembrolizumab)的专利即将到期,公司面临收入缺口,因此持续寻求弥补之策。通过此次交易,默克将获得维罗纳制药旗下治疗慢性阻塞性肺病(COPD)的药物Ohtuvayre(奥图瓦伊尔)。该...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.